Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Debt (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Total Debt for 12 consecutive years, with $584.7 million as the latest value for Q4 2025.

  • Quarterly Total Debt rose 51.86% to $584.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $584.7 million through Dec 2025, up 51.86% year-over-year, with the annual reading at $584.7 million for FY2025, 51.86% up from the prior year.
  • Total Debt hit $584.7 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $584.5 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $599.1 million in Q2 2023 to a low of $112.9 million in Q2 2021.
  • Historically, Total Debt has averaged $394.1 million across 5 years, with a median of $425.0 million in 2024.
  • Biggest five-year swings in Total Debt: decreased 29.06% in 2024 and later soared 51.86% in 2025.
  • Year by year, Total Debt stood at $116.9 million in 2021, then rose by 3.19% to $120.6 million in 2022, then soared by 314.29% to $499.6 million in 2023, then decreased by 22.93% to $385.0 million in 2024, then surged by 51.86% to $584.7 million in 2025.
  • Business Quant data shows Total Debt for IRWD at $584.7 million in Q4 2025, $584.5 million in Q3 2025, and $584.3 million in Q2 2025.